Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.

Category Primary study
JournalJournal of thrombosis and haemostasis : JTH
Year 2020
COVID-19 can be associated with coagulopathy (CAC, COVID-19-associated coagulopathy) with a high prothrombotic risk based on an intense inflammatory response to viral infection leading to immunothrombosis through different procoagulant pathways[1]. Emerging evidence suggests that the use of heparin in these patients could be associated with lower mortality[2].
Epistemonikos ID: f79c8ff52d3e803155048a8ce2ec8099d24a92e7
First added on: Jun 12, 2020